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Background. The pathogenic mechanisms and molecular
events involved in the development and progression of diabetic
nephropathy (DN) are not completely known. Recent data in-
dicate that diabetes includes an inflammatory component that is
related to diabetic complications. Tumor necrosis factor (TNF)-
a, a cytokine with mainly proinflammatory activity, may be syn-
thesized by renal cells. Our objective was to analyze intrarenal
TNF-a gene expression and its relationship with urinary albu-
min excretion (UAE). We also investigated the effect of inhi-
bition of angiotensin-converting enzyme on TNF-a expression
and UAE.
Methods. Streptozotocin-induced diabetic rats received
either no treatment or an angiotensin-converting enzyme in-
hibitor (enalapril). After eight weeks, renal expression of TNF-
a was evaluated by real-time polymerase chain reaction.
Results. Renal cortical messenger RNA levels of TNF-a in-
creased significantly and were twice as high in diabetic rats
than in nondiabetic control rats. Enalapril administration nearly
completely abolished the increase in TNF-a messenger RNA
expression to the level observed in control rats. UAE was sig-
nificantly correlated with urinary levels of TNF-a (r = 0.68, P <
0.05) and with renal TNF-a expression (r = 0.51, P < 0.05).
Conclusion. DN was associated with increased renal expres-
sion of TNF-a and UAE. Enalapril administration prevented
this enhanced expression of TNF-a and decreased urinary cy-
tokine excretion and albuminuria. These data provide a novel
insight into the pathogenic mechanisms of DN, and support the
hypothesis that inflammatory mechanisms may play a signifi-
cant role in the development and progression of renal injury
secondary to diabetes mellitus.
Diabetic nephropathy (DN) is the leading cause of re-
nal failure throughout the world. The exact pathogenic
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mechanisms and the molecular events leading to the de-
velopment and progression of this complication remain
incompletely understood.
The renin-angiotensin system (RAS) is critically im-
portant in the earliest glomerular hemodynamic distur-
bances observed in DN [1]. Angiotensin II (Ang II) is
another key factor regulating the expression and synthe-
sis of growth factors, chemokines, adhesion molecules,
and cytokines that are involved in processes such as cell
growth, apoptosis, fibrosis, and inflammation [2, 3].
There now are convincing data that diabetes includes
an inflammatory component thought to be related to di-
abetic complications. Plasma concentrations of inflam-
matory molecules, including proinflammatory cytokines,
are elevated in diabetic patients [4–6]. Recent studies
have shown that the concentrations of these substances
increase as nephropathy progresses [7, 8], and that these
inflammatory molecules are independently related to uri-
nary albumin excretion (UAE) [8, 9].
Cytokines are polypeptides that regulate immune and
inflammatory events. Tumor necrosis factor-a (TNF-a)
is a proinflammatory cytokine with a wide range of bio-
logic effects including the stimulation of the production of
prostaglandins, platelet-activating factor, and plasmino-
gen activator inhibitor; chemotaxis; the induction of ad-
hesion molecules expression; and the synthesis of other
inflammatory mediators [10, 11]. Renal cells are capable
of synthesizing TNF-a, which may act in a paracrine or
autocrine manner to induce a variety of effects on differ-
ent renal structures [10–12]. There is growing evidence
that proinflammatory cytokines play a significant role in
the development and progression of several renal disor-
ders [11], including DN [9, 13–15].
The aims of this preliminary study were to analyze the
intrarenal gene expression of TNF-a in streptozotocin-
induced diabetic rats and to investigate the relationship
between TNF-a expression and the urinary excretion of
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TNF-a and albumin. We also studied the effect of inhibi-
tion of angiotensin-converting enzyme (ACE) on these
variables.
METHODS
Animals and experimental model
Twelve-week-old male Sprague Dawley rats (Charles
River Laboratories, Barcelona, Spain) weighing 150 to
250 g were maintained on standard rodent chow and
given tap water ad libitum. The animals were housed
in a temperature-controlled (21 ± 1◦C) and humidity-
controlled (60 ± 10%) room with a 12-hour dark/light
cycle. Animals were treated according to the Directive
by the Council of the European Communities (86/609/
CEE) and the Directive by the European Parliament
(2003/65/CE) on the protection of animals used for ex-
perimental and other scientific purposes.
Experimental diabetes was induced by intraperitoneal
injection of 65 mg/kg streptozotocin (STZ; Sigma, St.
Louis, MO, USA) freshly dissolved in 0.9% sodium chlo-
ride. To confirm the diabetic state, blood glucose concen-
tration was measured three days after STZ injection. The
diabetic animals were divided into two groups (N = 6 in
each group): group A received no treatment and group
B received the ACE inhibitor enalapril maleate (Merck
& Co, Inc., Rahway, NJ, USA) dissolved in drinking wa-
ter (100 mg/L). None of the diabetic animals received
insulin treatment. Six animals served as nondiabetic con-
trols (group C).
After eight weeks of follow-up, all animals were anes-
thetized with an intraperitoneal injection of thiopental
(40 mg/kg) and bled completely by cardiac puncture. The
kidneys were removed rapidly from each rat. The right
kidney was decapsulated and the cortex excised, placed
on RNAlater stabilization solution (Ambion Inc., Austin,
TX, USA), and stored at −80◦C. The left kidney was fixed
in 10% phosphate-buffered formalin.
Total RNA isolation, reverse transcription, primers, and
real-time polymerase chain reaction
Total RNA was extracted from rat kidneys with
TRIreagent (SIGMA, Steinheim, Germany) as described
in the manufacturer’s instructions. Isolated RNA was
treated with 5 U of RNase-free, FPLC pure DNase I
(Amersham Pharmacia, Piscataway, NJ, USA) in the
presence of RNAguard RNase Inhibitor (Amersham
Pharmacia), followed by phenol-chloroform extraction.
Total RNA integrity was checked by agarose gel elec-
trophoresis and ethidium bromide staining, and was
subsequently used to synthesize cDNA with random hex-
amers using the First Strand cDNA Synthesis Kit (Roche,
Basel, Switzerland) with 20 U of AMV Reverse Tran-
scriptase at 42◦C.
Polymerase chain reaction (PCR) primers were de-
signed for an annealing temperature of 60◦C using Primer
3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3 www.cgi; Whiteheed Institute for Biomedical
Research, Cambridge, MA, USA), except for b-actin
primers, which also anneal at 60◦C. The primer constructs
(5′–3′ sequence) were: b-actin forward, TCCCTGGA-
GAAGAGCTACGA (size, 362 bp), and TNF-a forward,
CCACCACGCTCTTCTGT (150 bp). Reactions were
optimized to a final volume of 25 lL with 1 × reaction
buffer, 0.2 mmol/L of each deoxynucleotide, 2.5 mmol/L
MgCl2, 0.15 lmol/L of each primer, 1:100,000 SYBR
Green I (Molecular Probes, Leiden, Netherlands), and
0.4 U of HotStart DNA Taq Polymerase (Ecogen/Bio-
line, Madrid, Spain). Fluorescein was added to a final
dilution of 1:100,000 to normalize any differences in the
amount of intercalating dyes caused by pipetting errors.
Real-time PCR amplification was performed on an
iCycler iQ Real Time PCR system (BioRad, Hercules,
CA, USA) and analyzed with the provided software
(iCycler software version 3.0). A three-step run protocol
was used: (1) an initial hold of nine minutes at 95◦C to
activate Taq polymerase and a fluorescence measure-
ment to normalize the whole plate amount of fluorescein
dye; (2) an amplification and quantification cycle with
45 repeats (denaturation 20 seconds at 95◦C, annealing
20 seconds at 60◦C and extension 20 seconds at 72◦C
with a fluorescence measurement); and (3) a melting
curve analysis from 65◦C to 95◦C to check the specificity
of the amplified product. Agarose gel electrophoresis
was performed to confirm single-product amplifications
without primer dimers. All fragments were also checked
for specificity by direct sequencing of both strands with
an ABI PRISM 310 Genetic Analyzer using Big Dye
Terminator kit v 3.1 (Applied Biosystems, Foster City,
CA, USA). After PCR amplification, values of the thres-
hold cycle (Ct) were obtained for each sample and
defined as the point at which the fluorescence rises app-
reciably above the background fluorescence. To obtain
the relative expression level, the Ct value of each gene
of interest was normalized to the Ct value of the
housekeeping b-actin gene. The expression level of
cytokine mRNA was expressed as an arbitrary ratio of
the quantity of RNA to that of b-actin.
Laboratory analysis and cytokine measurements
Serum blood glucose concentration was determined
by standard techniques. Urine samples were collected
from rats housed in metabolic cages. Urinary excretion of
TNF-a was measured by enzyme-linked immunosorbent
assay using specific kits (Bender MedSystems GmbH,
Vienna, Austria). The sensitivity was 17 pg/mL, and the
intra- and inter-assay precision was <5% and 10%, re-
spectively. Urinary albumin excretion was measured by
nephelometry.
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Table 1. Physiologic and metabolic data at baseline and the end of
the study
Variable Group Baseline Eight weeks
Body weight g
Diabetic 198 ± 34 204 ± 60a
Diabetics + enalapril 227 ± 25 238 ± 54a
Nondiabetic control 190 ± 34 288 ± 52
Blood glucose mg/dL
Diabetic 234 ± 16b 300 ± 92b
Diabetics + enalapril 313 ± 14b,c 295 ± 71b
Nondiabetic control 77 ± 8 88 ± 17
Baseline, 72 hours after streptozotocin injection.
aP < 0.05.
bP < 0.01 vs. nondiabetic control group.
cP < 0.01, dP < 0.05 vs. diabetic group.
Statistical analysis
Results are expressed as mean ± SD, except for TNF-
a data, which are presented as median and range. Data
from the three groups were compared using Kruskal-
Wallis analysis of variance. Regression analysis was per-
formed with the Spearman rank correlation test. P <
0.05 was considered significant. Statistical analyses were
performed using Statistica 5.5 (Statsoft Inc., Tulsa, OK,
USA).
RESULTS
Table 1 summarizes the animals’ body weights and
blood glucose concentrations at baseline (72 hours after
STZ injection) and after eight weeks of follow-up. Blood
glucose concentration was significantly higher in diabetic
than in nondiabetic animals. The blood glucose concen-
tration did not differ significantly between diabetic rats
treated with enalapril (group B) and untreated diabetic
rats (group A). Basal mean body weights were similar
between the three groups. However, at the end of the
study, body weights were significantly lower in diabetic
rats (groups A and B) than nondiabetic animals (group
C); body weight did not differ significantly between dia-
betic groups A and B.
The mean basal levels of b-actin mRNA were simi-
lar between groups for each set of PCR reactions, con-
firming that the starting concentrations of cDNA were
similar and not subjected to systematic error. The expres-
sion level of TNF-a at the end of the study in diabetic
rats (group A) was more than double the value in con-
trol animals (group C) (Fig. 1). Interestingly, treatment
with enalapril virtually abolished the elevation in mRNA
levels for TNF-a so that the expression level in enalapril-
treated rats (group B) did not differ significantly from
that in control rats (Fig. 1).
TNF-a was not detectable in the urine of four control
rats. In contrast, urinary levels of TNF-a were detectable
in all untreated diabetic rats. In rats receiving enalapril,
TNF-a was not detectable in two animals, and the average

















Fig. 1. Quantitation of mRNA (normalized expression) for the proin-
flammatory cytokine TNF-a in untreated diabetic rats (group A),
enalapril-treated diabetic rats (group B), and nondiabetic control rats
(group C). ∗P < 0.05 vs. groups B and C.
urinary concentration in the other four rats (22.8 pg/mL;
range, 11.3–30.1) did not differ from the value in the con-
trol animals (13.5 pg/mL; range, 11.8–15.9) but was signifi-
cantly lower than in untreated animals (109 pg/mL; range,
89.4–142; P < 0.01). Basal UAE did not differ between
groups. However, at the end of the study, UAE was sig-
nificantly higher in untreated diabetic rats (10.6 mg/day;
range, 7.44–18.2) than in enalapril-treated (1.1 mg/day;
range, 0.66–2.43) and control rats (1.98 mg/day; range,
0.69–3.7) (P < 0.01 for each). UAE did not differ signifi-
cantly between groups B and C.
The urinary level of TNF-a was significantly correlated
with renal expression of TNF-a (r = 0.60, P < 0.05) and
with UAE (r = 0.68, P < 0.05). Renal expression of TNF-
a was significantly correlated with UAE (r = 0.51, P <
0.05).
DISCUSSION
The levels of proinflammatory cytokines increase
in diabetic patients, suggesting that inflammation may
be related to diabetic complications [4–9, 16]. In
1991, Hasegawa et al [15] reported that peritoneal
macrophages incubated with glomerular basement mem-
branes from diabetic rats produced greater levels of TNF-
a and interleukin (IL)-1 than macrophages incubated
with membranes from normal rats. These authors sug-
gested that proinflammatory cytokines might be involved
in the development of DN. Previous studies have shown
that mRNA levels of TNF-a increase in the glomeruli
of diabetic rats for a long time (24 and 52 weeks) af-
ter induction of diabetes [17, 18]. In contrast, a recent
study showed that TNF-a mRNA increases in proximal
tubule cells isolated from diabetic rats as early as 10 days
after induction of diabetes [19]. Nakamura et al [17] re-
ported a doubling of TNF-a mRNA expression in the
glomeruli of diabetic rats after four weeks and tripling
after 12 weeks. In our study, eight weeks after induction
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of diabetes, TNF-a mRNA expression was more than
double the basal level, an intermediate value to those
observed by Nakamura et al.
TNF-a is one of the main proinflammatory cytokines
and may be produced intrinsically in renal cells [20]. It
is important to note that increased urinary and renal
interstitial concentrations of TNF-a precede the rise in
albuminuria [21, 22]. TNF-a is cytotoxic to glomerular,
mesangial, and epithelial cells, and may induce direct re-
nal damage [23, 24]. Moreover, TNF-a has a direct ef-
fect on the protein permeability barrier of the glomerulus
[25], independent of alterations in hemodynamic factors
or effects of recruited inflammatory cells. In our study,
TNF-a expression was closely related to its urinary ex-
cretion, and urinary excretion of TNF-a was positively
correlated with UAE. Interestingly, the decrease in TNF-
a mRNA expression after enalapril treatment was asso-
ciated with a reduction in both albuminuria and urinary
TNF-a excretion to levels similar to those observed in
nondiabetic control rats. These findings strongly suggest
an intrarenal production of TNF-a, which may have a role
in the development and progression of renal damage in
DN.
Ang II has important effects beyond its hemodynamic
actions, including regulation of cell growth and extracel-
lular matrix production, and shares many intracellular
signaling mechanisms with classic cytokines. Several cel-
lular events are attributed to the newly identified prop-
erties of Ang II, which seem to coincide with key steps
in inflammation [2, 3]. Recent data show that Ang II is
a critical factor in the regulation of proinflammatory cy-
tokine gene expression and synthesis, and that human pe-
ripheral monocytes are able to produce TNF-a and IL-1
when stimulated with Ang II [26, 27]. In rat renal resi-
dent macrophages, Ang II upregulates TNF-a and IL-6
gene expression [28], and incubation of tubules from the
medullary thick ascending limb with Ang II promotes
accumulation of TNF-a mRNA [29]. Moreover, Ang II
infusion into normal rats stimulates renal production of
the proinflammatory cytokines TNF-a and IL-6 [30]. We
hypothesize that other angiotensin-dependent processes,
such as those related to proinflammatory cytokine regu-
lation, may play a significant role in the development and
progression of DN.
Evidence now indicates that inflammatory phenomena
are also involved in translating the primary metabolic and
hemodynamic insults into renal damage in DN [21, 22, 31,
32]. Modulation of these inflammatory processes might
be useful in preventing or designing therapeutic agents
for this complication. Utimura et al [33] demonstrated
that treating development of DN can be prevented by
treating diabetic rats with mycophenolate mofetil, and
that these actions were related to its antiproliferative
and anti-inflammatory properties instead of favorable
metabolic or hemodynamic effects. In a recent study,
DiPetrillo et al [19] showed that treatment of diabetic rats
with pentoxifylline, a substance with anti-TNF-a proper-
ties, decreased renal TNF-a expression and urinary TNF-
a excretion. Other studies have shown that pentoxifylline
administration to diabetic patients significantly reduces
urinary protein excretion and TNF-a levels [34–36], and
that the reduced proteinuria is significantly associated
with the decrease in TNF-a [35, 36].
Accumulating evidence implies that ACE inhibitors
have beneficial properties beyond their originally iden-
tified effects. Modulating inflammatory phenomena by
blocking the RAS in DN is of great interest. Our study
showed that the ACE inhibitor enalapril normalized the
renal overexpression of TNF-a in diabetic rats, and that
this effect was associated with a significant reduction in
renal cytokine production and UAE. Previous experi-
mental investigations have shown that ACE inhibitors
have potent inhibitory effects on proinflammatory cy-
tokine expression and synthesis [37–39]. Clinical stud-
ies in patients with congestive heart failure or advanced
chronic renal disease have demonstrated that therapy
with ACE inhibitors decreases TNF-a and IL-6 activity
[40, 41].
CONCLUSION
Our data show that TNF-a, one of the main proinflam-
matory cytokines, is overexpressed in a rat model of DN,
and that this overexpression is significantly associated
with evidence of renal damage, such as UAE. Blockade
of RAS by enalapril prevents the enhanced expression
of TNF-a and reduces UAE. These data provide a novel
insight into the pathogenic mechanisms of DN, and sup-
port the hypothesis that inflammatory phenomena, along
with regulatory effects mediated by Ang II, may play a
significant role in renal injury secondary to diabetes mel-
litus. Our data also suggest a need to study the potential
renoprotective effects of therapies that modulate inflam-
matory processes.
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